چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Background Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. Methods In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay. Results The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241). Conclusions There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19. |
| نویسنده | نفر چندم مقاله |
|---|---|
| مسعود نوری وسکه | اول |
| نیوشا کلامی | دوم |
| مجتبی ورشوچی فرد | پنجم |
| خلیل انصارین | ششم |
| هاله رضائی | هفتم |
| علی تقی زادیه | هشتم |
| آرمین صادقی | نهم |
| مسعود آهنگری ملکی | دهم |
| اعظم اسمعیل نژاد | یازدهم |
| پرویز صالح | دوازدهم |
| سید مهدی حق دوست | سیزدهم |
| مهدی ملکی | چهاردهم |
| اکبر شریفی | پانزدهم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| kalami.pdf | 1400/02/30 | 762053 | دانلود |
